Abstract

The glioblastoma microenvironment predominantly contains tumor-associated macrophages that support tumor growth and invasion. We investigated the relationship between tumor radiosensitivity and infiltrating M1/M2 macrophage profiles in public datasets of primary and recurrent glioblastoma. We estimated the radiosensitivity index (RSI) score based on gene expression rankings. Macrophages were profiled using the deconvolution algorithm CIBERSORTx. Samples from The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), the Ivy Glioblastoma Atlas Project dataset, a single-cell RNA sequencing dataset (GSE84465), Glioma Longitudinal Analysis Consortium (GLASS), and an immunotherapy trial dataset (GSE121810) were included. RSI-high radioresistant tumors were associated with worse overall survival in TCGA and CGGA than RSI-low tumors. M1/M2 macrophage ratios and RSI scores were inversely associated, indicating that radioresistant glioblastoma tumor microenvironments contain more M2 than M1 macrophages. In the single-cell RNA sequencing dataset, the mean RSI of neoplastic cells was positively correlated with high M2 macrophages proportions. A favorable response to programmed cell death protein 1 (PD-1) therapy was observed in recurrent glioblastomas with high M1/M2 macrophage ratios and low RSI scores. In patients with recurrent glioblastoma, fewer M2 macrophages and low RSI scores were associated with improved overall survival. High M2 macrophage proportions may be involved in radioresistant glioblastoma.

Highlights

  • Checkpoint blockade immunotherapy has demonstrated remarkable success in several types of solid tumors

  • We investigated the relationship between M1 macrophage (M1) and M2 macrophage profiles and radiosensitivity, represented as radiosensitivity index (RSI) scores, and their impacts on survival in patients with glioblastoma

  • The M1/M2 macrophage and recurrent tumors, differential macrophage gene expression was observed between ratio and the RSI score combined with the M2 macrophage proportion demonstrated the these two tumor types

Read more

Summary

Introduction

Checkpoint blockade immunotherapy has demonstrated remarkable success in several types of solid tumors. A recent trial of immune checkpoint blockades for recurrent glioblastoma, CheckMate 143 [1], showed limited efficacy. Only 8% of study patients showed an objective response in the CheckMate 143 trial, which may be explained by T-cell exhaustion in the tumor microenvironment [2]. The majority of immune cells in glioblastoma tumors consist of microglia and macrophages rather than T cells [3,4]. Macrophage polarized into having this phenotype is defined as M2 macrophage [12]. Macrophage can be polarized into the opposite phenotype to M2, which refers to M1 macrophage. Favorable or unfavorable immune microenvironment in glioblastoma may depend on polarized status in macrophage phenotype between M1 and M2.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call